title: TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy.
abstract: OBJECTIVE
  Transforming growth factor beta1 gene (TGFB1) variant Leu10Pro (L10P) has previously been implicated in prostate cancer risk and radiation-induced side-effects. We investigated whether prevalence of this polymorphism is increased in prostate cancer patients and whether carriers are at increased risk for treatment-related side effects.
  
  
  METHODS
  A series of 445 consecutive patients treated for early-stage prostate cancer receiving definitive I-125 brachytherapy (permanent seed implantation) between 10/2000 and 10/2007 at our institution and a comparison group of 457 healthy male control individuals were screened for TGFB1 L10P (869T>C) polymorphism. Morbidity was assessed prospectively and compared between carriers versus non-carriers using International Prostate Symptom Score (IPSS), disease-specific Quality-of-Life single question added to the IPSS and International Index of Erectile Function with its subgroups.
  
  
  RESULTS
  The Leu/Leu genotype was found in 150 patients (34%) versus 180 controls (39%), the Pro/Pro genotype in 75 patients (17%) versus 65 controls (14%) and the Leu/Pro genotype in 220 patients (49%) versus 212 controls (46%) without any statistically significant differences between the two groups. There was a trend towards an increased prevalence of the L10P substitution among patients with a per allele odds ratio of 1.19 (95% CI 0.99-1.44; P = 0.08). After a median follow-up of 18 months (range 1-60 months) there were no statistically significant differences regarding morbidity.
  
  
  CONCLUSIONS
  TGFB1 polymorphism L10P is not strongly associated with prostate cancer risk. After 18 months, there was no evidence for increased adverse radiotherapy responses in heterozygote or rare homozygote carriers. Longer follow-up may be necessary to detect a statistically significant difference.
authors.affiliation: Clinics of Radiation Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany. Meyer.A@mh-hannover.de
authors.forename: Andreas
authors.initials: A
authors.lastname: Meyer
authors.forename: Thilo
authors.initials: T
authors.lastname: Dörk
authors.forename: Natalia
authors.initials: N
authors.lastname: Bogdanova
authors.forename: Maria-Jantje
authors.initials: MJ
authors.lastname: Brinkhaus
authors.forename: Birgitt
authors.initials: B
authors.lastname: Wiese
authors.forename: Jörn
authors.initials: J
authors.lastname: Hagemann
authors.forename: Jürgen
authors.initials: J
authors.lastname: Serth
authors.forename: Michael
authors.initials: M
authors.lastname: Bremer
authors.forename: Rolf
authors.initials: R
authors.lastname: Baumann
authors.forename: Johann H
authors.initials: JH
authors.lastname: Karstens
authors.forename: Stefan
authors.initials: S
authors.lastname: Machtens
mesh_terms: D000368:Aged; D001918:Brachytherapy; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000532:radiotherapy*; D011788:Quality of Life; D053773:Transforming Growth Factor beta1 / Q000235:genetics*
chemical_list: C508960:TGFB1 protein, human; D053773:Transforming Growth Factor beta1